InnoCare Pharma (9969) H1 2024 earnings summary

Executive summary

• Achieved strong revenue growth in H1 2024, driven by a 30% year-over-year increase in orelabrutinib sales, with total revenue reaching RMB419.7 million and expanded market penetration in China and globally.

• Loss for the period narrowed by 37.6% to RMB268.0 million, attributed to drug sales growth, cost improvements, and reduced non-cash expenses.

• Gross profit margin improved to 85.7%, up from 79.9% in the prior period, supported by a favorable sales mix.

• Maintained a robust cash position of RMB7.99–8 billion as of June 30, 2024, supporting long-term development and operational flexibility.

• Advanced multiple clinical assets in oncology, autoimmune, and solid tumor indications, with several NDAs and BLAs submitted and key trials progressing.

Financial highlights

• Orelabrutinib revenue reached RMB417.0 million in H1 2024, up 30% year-over-year; Q2 drug sales increased 49% year-over-year.

• Total revenue for H1 2024 was RMB419.7 million (+11.2% YoY); gross profit: RMB359.6 million (+19.3% YoY); gross margin: 85.7%.

• Net loss narrowed by 37.6% year-over-year, from RMB429.2 million to RMB268.0 million; adjusted loss: RMB243.0 million.

• R&D expenses increased by 17.5% to RMB420.8–421 million, reflecting strategic investment in clinical trials and technology platforms.

• Cash and equivalents at period end were RMB7.99 billion, with strong liquidity and flexibility for R&D and pipeline investment.

Outlook and guidance

• Full-year orelabrutinib revenue growth guidance raised to at least 35%, implying over 40% growth in H2 2024.

• Anticipates break-even by 2027 or 2028, with potential acceleration if business development deals close.

• Expects continued robust growth in Q3 and Q4, with no weakening of key growth drivers and pivotal pipeline milestones ahead.

• Focused on expanding global R&D, commercialization, and manufacturing capabilities, with a transition to a more globally integrated business model.

• Plans to further develop hemato-oncology franchise, advance autoimmune disease therapies, and build a competitive solid tumor portfolio.